Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Diana Luft"'
Autor:
Diana Luft
OPEN ACCESS To view Medieval Welsh Medical Texts for free click on the following links: https://www.uwp.co.uk/app/uploads/MWMT_final_low-res-1.pdf https://www.ncbi.nlm.nih.gov/books/NBK558253/ This volume presents the first critical edition and trans
Autor:
Philipp Ziegler, Andreas D. Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Laura L. Michel, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Hanna Huebner, Sabrina Uhrig, Lena A. Wurmthaler, Carolin C. Hack, Christoph Mundhenke, Christian Kurbacher, Peter A. Fasching, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss, Chloë Goossens
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the d
Externí odkaz:
https://doaj.org/article/f6addaf5728b4463afe3407a59ff7008
Autor:
Peter A. Fasching, Chunling Hu, Steven N. Hart, Matthias Ruebner, Eric C. Polley, Rohan D. Gnanaolivu, Andreas D. Hartkopf, Hanna Huebner, Wolfgang Janni, Peyman Hadji, Hans Tesch, Sabrina Uhrig, Johannes Ettl, Michael P. Lux, Diana Lüftner, Markus Wallwiener, Lena A. Wurmthaler, Chloë Goossens, Volkmar Müller, Matthias W. Beckmann, Alexander Hein, Daniel Anetsberger, Erik Belleville, Pauline Wimberger, Michael Untch, Arif B. Ekici, Hans-Christian Kolberg, Arndt Hartmann, Florin-Andrei Taran, Tanja N. Fehm, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Lothar Häberle, Fergus J. Couch
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2−) advanced breast cancer (aBC). However, little is known about the prognostic impact of gBRCA1/2 mutations in a
Externí odkaz:
https://doaj.org/article/7fc65e7d8ec9445caafcbb4945b9c522
Autor:
Diana Luft
Publikováno v:
Studia Celtica. 53:103-132
This article advances the argument that the fourteenth-century Welsh medical manuscript British Library Additional 14912 is based on materials which ultimately stem from Llanthony Prima Priory in Monmouthshire, although it may itself have been produc
Publikováno v:
Access Microbiology. 1
Autor:
Diana Luft
Publikováno v:
The Cambridge History of Welsh Literature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75296d6c897cef0ac2df3c822bbb1ea9
https://doi.org/10.1017/9781316227206.006
https://doi.org/10.1017/9781316227206.006
Autor:
Diana Luft
Publikováno v:
Translation Studies. 9:168-182
The twentieth-century editors of medieval Welsh translated texts did not have an entirely positive attitude towards their subject of study. They claimed that these texts were marred by poor style, and riddled with grammatical errors which were the re
Autor:
Tom Degenhardt, Peter A. Fasching, Diana Lüftner, Volkmar Müller, Christoph Thomssen, Christian Schem, Isabell Witzel, Thomas Decker, Hans Tesch, Sherko Kümmel, Christoph Uleer, Rachel Wuerstlein, Oliver Hoffmann, Mathias Warm, Norbert Marschner, Timo Schinköthe, Ronald E. Kates, Johannes Schumacher, Burkhard Otremba, Matthias Zaiss, Nadia Harbeck, Marcus Schmidt, on behalf of the PreCycle Investigators
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, addition of targete
Externí odkaz:
https://doaj.org/article/3808c31034b14f1e8fdee7d4201422ec
Autor:
Diana Luft
Publikováno v:
Zeitschrift für celtische Philologie. 58:55-86
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 54, Iss , Pp 88-95 (2020)
Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of th
Externí odkaz:
https://doaj.org/article/06b4953fd7094428a800955c7f592096